Medical research organization NAMSA said it has acquired Reimbursement Strategies, a Minneapolis-based consultancy focused on reimbursement, health economics and market access for the international life science industry.
Toledo, Ohio-based NAMSA is a medical device development firm that offers integrated laboratory testing, clinical research and regulatory consulting services. Similar to NAMSA, Reimbursement Strategies concentrates on reimbursement strategy, health economics, medical policy research, and coverage advocacy. The companies have worked together for some time.
“We are extremely excited about the acquisition of Reimbursement Strategies,” said Christopher Rupp, VP of NAMSA’s global marketing and commercial operations, said in a statement. “The addition of this service will allow clients to proactively address the largest challenges of bringing novel devices to the global marketplace—securing appropriate coverage and payment for new and existing technologies. We look forward to delivering device manufacturers faster, more cost-effective commercialization results through our comprehensive, full-service development solution.”
“We are very pleased to join the NAMSA team as we work together to provide clients the most critical services required to navigate our industry’s complicated global reimbursement landscape,” added former Reimbursement Strategies president Edward Black, who now serves as NAMSA’s director of global reimbursement strategy.
NAMSA operates 13 offices throughout North America, Europe, the Middle East, and Asia, and employs nearly 1,000 laboratory, clinical and consulting associates.
